The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Krina Patel, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the updated results from the iMMagine-1 study (NCT05396885), a Phase II registrational trial of anitocabtagene autoleucel (anito-cel) in patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Patel highlights the highly encouraging safety and efficacy data observed with this CAR T-cell construct thus far, including promising rates and depth of response, as well as a favorable safety profile. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
